We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.50 | 22.00 | 25.00 | 4,000 | 15:22:53 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.95 | 18.16M |
From Apr 2019 to Apr 2024
TIDMONC
RNS Number : 1020D
Oncimmune Holdings PLC
24 April 2017
24 April 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
GRANT OF OPTIONS
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, announces that on 21 April 2017, options over 23,872 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to certain US staff under the Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009). The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 20 April 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 131 pence, being the mid-market closing price of the Ordinary Shares on 20 April 2017.
The Company also announces that on 21 April 2017, options over 30,534 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to a member of UK staff under the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan. The options are subject to the rules of the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan and vest in five equal annual parts, the first fifth vesting on 8 January 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 131 pence, being the mid-market closing price of the Ordinary Shares on 20 April 2017.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGIGDSUBDBGRS
(END) Dow Jones Newswires
April 24, 2017 04:18 ET (08:18 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
